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Abstract
Background: The trophoblast Kunitz domain proteins (TKDPs) constitute a highly expressed,
placenta-specific, multigene family restricted to ruminant ungulates and characterized by a C-
terminal "Kunitz" domain, preceded by one or more unique N-terminal domains. TKDP-1 shares
an almost identical expression pattern with interferon-tau, the "maternal recognition of
pregnancy protein" in ruminants. Our goal here has been to determine whether the ovine (ov)
Tkdp-1 and IFNT genes possess a similar transcriptional code.
Results:  The  ovTkdp-1  promoter has been cloned and characterized. As with the IFNT
promoter, the Tkdp-1 promoter is responsive to Ets-2, and promoter-driven reporter activity
can be increased over 700-fold in response to over-expression of Ets-2 and a constitutively
active form of protein Kinase A (PKA). Unexpectedly, the promoter element of Tkdp-1
responsible for this up-regulation, unlike that of the IFNT, does not bind Ets-2. However,
mutation of a CCAAT/enhancer binding element within this control region not only reduced
basal transcriptional activity, but prevented Ets-2 as well as cyclic adenosine 5'-monophosphate
(cAMP)/PKA and Ras/mitogen-activated protein kinase (MAPK) responsiveness. In vitro binding
experiments and in vivo protein-protein interaction assays implicated CCAAT/enhancer binding
protein-beta (C/EBP-β) as involved in up-regulating the Tkdp-1 promoter activity. A combination
of Ets-2 and C/EBP-β can up-regulate expression of the minimal Tkdp-1 promoter as much as
930-fold in presence of a cAMP analog. An AP-1-like element adjacent to the CCAAT enhancer,
which binds Jun family members, is required for basal and cAMP/ C/EBP-β-dependent activation
of the gene, but not for Ets-2-dependent activity.
Conclusion: This paper demonstrates how Ets-2, a key transcription factor for trophoblast
differentiation and function, can control expression of two genes (Tkdp-1 and IFNT) having similar
spatial and temporal expression patterns via very different mechanisms.
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Background
The trophoblast Kunitz domain proteins are a family of
closely related gene products uniquely expressed by tro-
phoblast of ruminant ungulates [1,2]. Each protein is
characterized by the presence of a well-conserved, car-
boxyl-terminal ~65 amino acid domain, typically found
in the Kunitz family of serine peptidase inhibitors. The
Kunitz domain is an evolutionary conserved module,
existing in C. elegans, D. melanogaster, and all known ver-
tebrates, that generally functions as a serine peptidase
inhibitor, although functions unrelated to peptidase inhi-
bition have also been documented [3-6]. This independ-
ently folding unit is preceded by one or more "repeat"
sequences of ~80 amino acids of unknown function,
which have similar but not identical sequences [1,2].
TKDPs represent one of the most abundant classes of
secretory proteins produced by the conceptus during the
peri-implantation period and throughout gestation
[1,2,7,8]. Although the function of these proteins remains
unclear, their unusually high expression at the interface
between the maternal and fetal systems and the presence
of conserved Kunitz units at their carboxyl termini
strongly suggest an important role during pregnancy that
relates to the evolution of the non-invasive placental type
encountered in ruminant species.
Although expressed abundantly, the concentrations of dif-
ferent TKDP mRNAs do not remain constant over the
course of pregnancy. Instead, expression of each TKDP
appears to be quite tightly regulated and confined to spe-
cific stages of fetal development. For example, ovTKDP-1
and its bovine ortholog (boTKDP-1) are expressed signif-
icantly for just a few days preceding the period when the
trophoblast begins to adhere tightly to the uterine wall [2]
In this respect, the temporal expression pattern of TKDP-
1 and that of IFN-τ, the major signal for maternal recogni-
tion of pregnancy in cattle and sheep are remarkably sim-
ilar. For example, both TKDP-1 and IFN-t are secreted by
the trophoblast mononuclear cells during days 13–21 of
pregnancy in sheep [7]. In view of the physiological
importance of IFN-τ in ensuring the survival of the con-
ceptus [9,10] and the fact that both TKDP-1 and IFN-τ are
up-regulated massively and simultaneously at a particular
critical time when many embryos are lost, it seems likely
that ovTKDP-1 has some function important for mediat-
ing maternal-conceptus interaction during the peri-attach-
ment/implantation period of conceptus development.
The strikingly similar spatial-temporal expression pattern
of TKDP-1 and IFN-τ raises the possibility that these genes
(Tkdp-1 and IFNT) representing these proteins are control-
led by very similar transcriptional mechanisms and possi-
bly share common transcription factor binding elements
in their promoter regions. The major focus of the current
research has been to gain insight into the control of Tkdp-
1 gene expression and to determine whether the mecha-
nisms involved resembled those associated with the regu-
lation of the IFNT. One important goal has been to
elucidate whether or not there is a common theme to the
transcriptional regulation of genes that are first expressed
as the trophoblast begins to differentiate functionally
early in pregnancy and secrete its signature gene products.
The outcome of this research could, therefore, have impli-
cations to the establishment and/or maintenance of preg-
nancy and the specification of trophoblast function in all
mammals.
The data presented here demonstrates Ets-2 having an
important role in activating the transcription of the
ovTkdp-1 gene in in vitro cell culture systems. However,
unlike the IFNT promoter, which directly interacts with
Ets-2 via consensus Ets-binding site, the Ets-2 effect on the
Tkdp-1 promoter is indirect and mediated by protein-pro-
tein interaction with C/EBP-β. In other words, Ets-2-
dependent transactivation of genes with nearly identical
spatial and temporal expression patterns can be mediated
by different mechanisms.
Results
Expression patterns of the ovTKDP-1 and IFN-τ messages 
during pregnancy
Although TKDP-1 and IFN-τ mRNA are expressed within
a comparable window of early pregnancy [7], side by side
comparisons have not been made. We therefore con-
ducted RT-PCR with equal quantities of RNA extracted
from sheep conceptuses collected at different days of early
pregnancy. The expression patterns for ovTKDP-1 and
ovIFN-τ mRNAs were similar both in magnitude and over
developmental time (Fig. 1A). Both transcripts were
detectable in sheep conceptuses at day 14 of pregnancy,
with concentrations peaking at day 15 and subsequently
declining after day 17 to become almost undetectable by
day 25 relative to the amplified product derived from the
endogenous control, ribosomal protein S25.
Constitutive transcriptional activities of the truncated 
promoter-Luciferase (Luc) reporter constructs from the 
Tkdp-1 gene in human choriocarcinoma JEG-3 cells
Different length fragments from 1 Kbp region upstream of
the transcription start point (tsp) of the Tkdp-1 gene were
used to generate seven sequentially 5/-truncated Tkdp-1
promoter-Luc reporter constructs (1000, 558, 352, 254,
192, 140 and 82 bp from the tsp). These constructs were
transiently transfected into JEG-3 cells and their expres-
sion compared relative to the Luc activity from the pro-
moter-less pGL2 Basic vector (Fig. 2). All but the 82 bp
promoter-reporter constructs were able to drive Luc
reporter gene significantly better than the promoter-less
reporter construct. The 1000 bp construct had the maxi-
mum basal promoter activity, and this activity wasBMC Molecular Biology 2007, 8:14 http://www.biomedcentral.com/1471-2199/8/14
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reduced significantly when the promoter was shortened to
558 bp. Promoter activity increased again in the 352, 254,
192 and 140 bp constructs, but was never completely
restored to that of the 1000 bp construct. These data sug-
gest that there are two enhancer/activator elements
present, one distal, between -558 and -1000 bp, and the
other more proximal, lying between 140 and 82 bp. There
may also be a cryptic repressor element lying between the
558 bp and 352 bp promoter fragments, although another
explanation for the poor activity of the 558 construct is
that it folds in such a way that it is less easily transcribed
than its longer and shorter relatives. Since the 140 bp con-
struct was the shortest one able to drive Luc expression
effectively, contained the proximal enhancer element, and
included several relevant transcription factor binding sites
(see below) our efforts became focused on this control
region of the gene.
Putative transcription factor-binding sites on theTkdp-1 
promoter
Fig. 3 illustrates putative transcription factor binding sites
within 140 bp upstream of the tsp of the Tkdp-1 promoter
that can also be identified within the boIFNT1 proximal
promoter (-126 to +50) and have been implicated in the
basal expression of IFNT genes in vitro [11,12]. No Ets-2/
AP-1 composite enhancer motif comparable to the one
essential for IFNT gene transcription is detectable within
the proximal 140 bp of the Tkdp-1 promoter, although a
number of potential Ets-factor binding elements are
present. None of these sites possesses a sequence identical
to the Ets-2-binding element found within the IFNT pro-
moter (-79 ACAGGAAGTG -70), although each does pos-
sess the central GGA motif that is an invariable feature of
all Ets-factor-binding sites [13,14] (Fig. 3 and additional
data file 1 – Fig. 1). A possible AP-1 element is present in
the Tkdp-1 promoter, but its sequence is different from
that of the one placed just upstream of the Ets-2-binding
site on all known IFNT genes (TGAGAGA versus TGAG/
CTCA) [11].
Effects of over-expressing Ets family transcription factors 
on the transcriptional activity of the Tkdp-1 promoter in 
JEG-3 cells
Although expressed widely in adult and embryonic tis-
sues, the Ets family transcription factor Ets-2 is crucial for
placental development [15]. It is also present in ovine
conceptus tissue at the time that IFN-τ is produced and is
known to support expression of several genes that are
restricted to trophoblast [16-22], including IFNT  [23].
Since the Tkdp-1  gene possesses several Ets-like sites
within its promoter region, transient transfection experi-
ments were performed to test the effects of over-expressing
several Ets family members on the transcriptional activity
of the 1000 bp promoter-reporter construct in JEG-3 cells
(Fig. 4A). In order to provide roughly comparable expres-
Detection of ovTKDP-1, IFN-τ, Ets-2 and C/EBP-β mRNA in  sheep trophectoderm Figure 1
Detection of ovTKDP-1, IFN-τ, Ets-2 and C/EBP-β 
mRNA in sheep trophectoderm. RT reactions were per-
formed on sheep trophoblast RNA collected from different 
days of pregnancy. After binding to oligo dT primer, reverse 
transcription and PCR amplification with primers specific for 
each message were performed. A) Comparison of ovTKDP-
1 and IFN-τ expression during the peri-implantation period 
of conceptus development. Lanes 1–3: positive control PCR 
with TKDP-1, IFN-τ and S25 plasmid templates, respectively; 
lanes 4–9: PCR with days 14, 15, 16, 17, 19 and 25 sheep tro-
phoblast cDNA. B) Ets-2 mRNA expression during the peri-
implantation period of conceptus development. Lane 1: DNA 
marker; lane 2: positive control PCR with Ets-2 expression 
plasmid; lanes 3–8: PCR with day 14, 15, 16, 17 and 25 
cDNA. C) C/EBP-β mRNA expression;. Lane 1: DNA 
marker; lane 2: positive control PCR with C/EBPβ expression 
plasmid; lanes 3–8: PCR with day 14, 15, 16, 17 and 25 
cDNA.
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sion, each of these Ets expression constructs was driven by
the same cytomegalovirus promoter, although protein
stability and other variables could not be controlled.
Among six different Ets-related transcription factors exam-
ined (Ets-1, Ets-2, Elf-1, Fli-1, PEA3, PU.1 and GABP-α,-β)
only Ets-1 and Ets-2 had significant ability to up-regulate
the transcriptional activity of the 1000 bp Tkdp-1  pro-
moter. Of the two, Ets-2 was clearly the superior (30-fold
versus 13-fold).
To examine which part of the Tkdp-1 promoter is respon-
sive to Ets-2, an equal amount of three truncated Tkdp-1
promoter-reporter constructs, 1000 bp, 352 bp and 140
bp, was co-transfected into JEG-3 cells with the Ets-2
expression plasmid. Ets-2 over-expression increased Luc
activity of all three constructs quite similarly (Fig. 4B),
although the 140 bp promoter was slightly more respon-
sive than the 1000 bp promoter (Fig. 4B: 28-fold for 1000
versus 34-fold for 140). These data suggested that the
region of the promoter targeted by Ets-2 is within 140 bp
of the tsp. We also tested the effect of Ets-2 over-expression
on the transcriptional activity of the promoter-less Luc
reporter vector (pGL-2 Basic) (data not shown). As
expected, Ets-2 had no significant effect on the reporter
expression in absence of a promoter, indicating that the
Ets-2-mediated activation of the Tkdp-1  promoter-Luc
construct is a promoter-specific effect.
Ets-2-mediated activation of the Tkdp-1  promoter was
dose-dependent (Fig. 4C). Differences in fold-activation
between experiments probably reflect the quality of the
plasmid DNA and other variables not easily controlled in
transfection studies. A time-course experiment was also
performed as a preliminary test to determine whether the
Ets-2-responsiveness of the ovTkdp-1 promoter is early or
delayed. An early response is indicative of a direct effect
while a delayed response would suggest Ets-2-mediated
up-regulation of some other transcription factor necessary
for expression of the Tkdp-1 gene. When JEG-3 cells, co-
transfected with Ets-2 and the 1000 bp ovTkdp-1 promoter
constructs, were harvested at various time points after
transfection (data not shown), Ets-2-responsiveness of the
Expression of a series of Tkdp-1 promoter-Luc reporter constructs transfected into JEG-3 cells Figure 2
Expression of a series of Tkdp-1 promoter-Luc reporter constructs transfected into JEG-3 cells. Luc activities are 
expressed relative to that of the promoter-less pGL2-Basic Luc reporter construct, with data shown as means ± SEM (n = 3; P 
< 0.05: pGL2 vs. 1000, 352, 254, 192, 140).
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1000 bp construct was clearly evident within 6 h of trans-
fection, suggesting that Ets-2 directly activates the Tkdp-1
promoter.
Ras/MAPK-mediated activation of theTkdp-1 promoter in 
3T3 cells
Ets-2 and the related transcription factor Ets-1 bind to spe-
cific DNA elements via their Ets domains, but often
require activation through Ras/MAPK-dependent phos-
phorylation at specific residues in order to participate
effectively in target gene transcription [11,16,24-28]. To
test whether the 1000 bp Tkdp-1 promoter-reporter con-
struct was similarly responsive to MAPK activation, it was
co-transfected with a constitutively active Ras expression
plasmid in presence and absence of Ets-2 in mouse fibrob-
last 3T3 cells. These mouse fibroblasts were used because,
unlike choriocarcinoma cells, they possess low endog-
enous levels of Ets-2 and activated Ras [11], so that the
effect of over-expression is easily demonstrable. Ras in
combination with Ets-2, but not by itself, caused a 21-fold
activation of the 1000 bp promoter construct (Fig. 5). This
stimulation of Tkdp-1  promoter activity was reduced
approximately 96% by treating the transfected cells with
the MAPK kinase (MEK1) inhibitor PD98059. If the
codon encoding the Ras/MAPK target site, Thr 72, was
mutated, Tkdp-1 promoter activity was reduced by about
50% compared to that obtained with the Ras and wild
type Ets-2 combination. These data show that the Tkdp-1
promoter can be up-regulated by the Ras/MAPK pathway
acting through Ets-2.
cAMP/PKA-mediated activation of the Tkdp-1 promoter in 
JEG-3 cells
The cAMP/PKA signaling pathway has been shown to
modulate the Ets-dependent activation of several tro-
phoblast-specific genes, including the human chorionic
gonadotropin (hCG)-α and β subunit genes [16,17] and
IFNT [17]. Treatment of JEG-3 cells with increasing con-
Possible transcription factor-binding sites in the proximal ovTkdp-1 and boIFNT1 promoters Figure 3
Possible transcription factor-binding sites in the proximal ovTkdp-1 and boIFNT1 promoters. The sequence of the 
Ets-AP-1 composite enhancer in the boIFNT1 promoter is also shown [23]. The tsp is designated +1.
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centrations of the cAMP analog, 8-Br-cAMP, after co-trans-
fecting the cells with the 1000 bp Tkdp-1  promoter-
reporter construct and the Ets-2 expression plasmid pro-
vided only a 2–3-fold enhancement of the Ets-2 effect
(Additional data file 1 – Fig. 2). 8-Br-cAMP alone, i.e. in
absence of over-expressed Ets-2, had no significant ability
to up-regulate the promoter (data not shown).
One possibility of explaining why 8-Br-cAMP had such a
minor effect on the Tkdp-1 promoter was that in JEG-3
cells PKA, the downstream target of cAMP, is present in
limiting amounts. Accordingly, the effects of a constitu-
tively active catalytic subunit of PKA were examined. As
shown in Fig. 6A, over-expression of the constitutively
active catalytic subunit of PKA led to a 120-fold up-regu-
lation of the basal activity of the 1000 bp Tkdp-1 promoter
in JEG-3 cells. When Ets-2 was also over-expressed, activ-
ity of the promoter was enhanced over 700-fold. The PKA
and PKA+Ets-2 effects on the Tkdp-1 promoter activation
were inhibited over 95% by expression of a PKA inhibitor
(PKI) construct (Fig. 6A). Additionally, substitution of the
plasmid expressing the active form of PKA with one with
a mutated catalytic site (mutPKA) failed to up-regulate the
Tkdp-1  promoter (Fig. 6A). Finally, treatment of trans-
fected cells with a pharmacological PKA inhibitor, H89,
caused dramatic reduction in promoter activity, both in
absence and presence of Ets-2, in a concentration-depend-
ent manner (Fig. 6B). These data indicate that the Tkdp-1
promoter is responsive to the cAMP/PKA signal transduc-
tion pathway and that Ets-2 acts synergistically with this
pathway to up-regulate this promoter.
Indirect interaction between Ets-2 and the Tkdp-1 
promoter
As mentioned previously, other than having the core GGA
sequence, none of the putative Ets-like sites within the
Tkdp-1 promoter showed a close match with either the
consensus Ets-2-binding motif (C/A)(C/A)GGA(A/T)(A/
G) or the well defined, functional site (CAGGAAG) in the
IFNT  promoter. In order to determine whether any of
these putative Ets-like sites within the Tkdp-1 promoter
binds Ets-2, competition electrophoretic mobility shift
assay (EMSA) was performed. The 140 bp minimal pro-
moter was chosen because it had multiple potential Ets-
like sites (Fig. 3) and provided full Ets-2 responsiveness
(Fig. 4B). Initial experiments in which we employed
EMSA to demonstrate an interaction between recom-
binant Ets-2 and oligonucleotides representing these
Transactivation of the Tkdp-1 promoter by Ets-2 Figure 4
Transactivation of the Tkdp-1 promoter by Ets-2. A) Effects of different Ets family transcription factors on reporter 
expression from the 1000 bp Tkdp-1 promoter-Luc reporter construct in JEG-3 cells. Luc activities (means ± SEM; n = 3) are 
expressed relative to that of the basal activity of the 1000 bp construct. Following values differ significantly (p < 0.05): 1000 vs. 
1000+Ets-1 and Ets-2; 1000+Ets-1 vs. 1000+Ets-2. B) Effect of Ets-2 on the transcriptional activities of three 5/-truncated Tkdp-
1 promoter-Luc reporter constructs 1000, 352 and 140 in JEG-3 cells. Luc activities are expressed relative to that of the basal 
activity of each of the truncated constructs and data are shown as mean ± SEM (n = 3). For each truncated construct, the fold-
induction in reporter activity after co-transfection with Ets-2 is significantly different from that without Ets-2 (P < 0.05). C) 
Effect of increasing concentrations of Ets-2 on the activity of the 1000 bp Tkdp-1 promoter-Luc reporter construct. Luc activi-
ties are expressed relative to that of the basal activity of the 1000 bp construct and data are shown as mean ± SEM (n = 3). Fol-
lowing values differ significantly (p < 0.05): 1000 vs. 0.5 μg, 0.9 μg, 1.3 μg and 1.5 μg Ets-2.
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potential Ets-binding sequences failed to reveal the forma-
tion of any complexes (data not shown). As shown in Fig.
7, none of the six potential competitor oligonucleotides
(lanes 5–10) was able to disrupt either the slower or faster
migrating DNA-protein complexes formed between the
32P-labeled Ets consensus oligonucleotide and ovEts-2-
GST-fusion protein (lanes 1 and 3). The slight variation in
intensities in the faster and slower migrating specific com-
plexes across lanes 5–10 likely resulted from differences in
gel loading. EMSA experiments employing labeled oligo-
nucleotides representing the putative Ets-binding sites
within the 140 bp promoter failed to provide specific
complexes with recombinant Ets-2 (data not shown).
Together, these results indicate that Ets-2 is unable to
associate with the proximal promoter and that none of the
putative Ets-binding sites present is likely to be functional.
Activation of the Tkdp-1 promoter by C/EBPs in JEG-3 cells
C/EBPs are basic-leucine zipper transcription factors,
comprising of six family members (-α, -β, -γ, -δ, -ε and -ξ)
[29]. C/EBP proteins are known to interact with Ets family
members [30-33]. The 140 bp Tkdp-1 promoter possesses
a consensus CCAAT/enhancer element (TTATGCAAT)
[34] located between -117 and -109 bp (Fig. 3). Accord-
ingly, determined whether the 140 bp Tkdp-1 promoter
construct was responsive to over-expression of three C/
EBP family members (-α, -β and -δ) (Fig. 8A). None of the
three C/EBP family members used here had an effect on
the basal promoter activity, and only a slight increase was
observed in presence of Ets-2. When Ets-2 was over-
expressed in presence of 250 μM 8-Br-cAMP (Fig. 8B) each
family member further up-regulated the Tkdp-1 promoter
activity, with C/EBP-β being the most potent. Together,
these results suggest that the Ets-2/cAMP/PKA effect on
the promoter noted in Fig. 6 is possibly mediated through
C/EBP-β.
Mutation of the C/EBP binding site in theTkdp-1 minimal 
promoter reduces its activity
When the CCAAT/enhancer element (TTATGCAAT) of the
140 bp Tkdp-1 promoter-reporter construct was mutated
(TTATcCccc) both the basal transcriptional activity and
the effects of Ets-2, PKA and Ets-2+PKA were markedly
reduced (~90 %) compared to the wild type promoter in
JEG-3 cells (Fig. 9A). That the C/EBP-binding site muta-
tion had no additional effect on Ets-2-dependent than on
basal promoter activation was somewhat surprising,
However, basal promoter activity is quite high in JEG-3
cells, e.g. compared to the non-trophobast cell line,
NIH3T3, possibly because of the higher content of endog-
enous Ets2 and other essential transcription factors
present in these trophoblast cells. Accordingly, the effect
of the mutation on basal activity may be difficult to distin-
guish from the effect observed when Ets-2 is expressed
ectopically. Reduction in the basal promoter activity and
the Ets-2 or Ets-2+Ras responsiveness was also observed in
the 3T3 mouse fibroblast cell line when the CCAAT/
enhancer element was mutated (Fig. 9B), and, the effect of
the mutation when Ets-2 was over-expressed was more
pronounced. Thus, mutation of the CCAAT/enhancer ele-
ment largely eliminated the promoter's ability to respond
to Ets-2 and the cAMP/PKA or the Ras/MAPK signal trans-
duction pathways. These data along with our earlier
observation (Fig. 8A) that C/EBP-α, -β or -δ has no effect
on the reporter gene expression by its own, suggest that
the effects of PKA, Ets-2, Ets-2+PKA and Ets-2+Ras on the
140 bp Tkdp-1 promoter are mediated through the C/EBP-
binding site, conceivably through a direct interaction of
Ets-2 with C/EBP-β.
C/EBP-β directly interacts with theTkdp-1 promoter
In order to identify which of the three C/EBP family mem-
bers used in the transfection experiments (Fig. 8A and 8B)
interacts with the 140 bp promoter in vitro, we performed
EMSA with a 32P-labeled double-stranded (ds) oligonu-
cleotide possessing the C/EBP-binding site of the Tkdp-1
promoter, JEG-3 cell extracts, and antibodies specific for
C/EBP-α, -β, and -δ (Fig. 10). As shown in lane 1, a specific
DNA-protein complex was formed between the CCAAT/
enhancer element and JEG-3 cell extracts. Excess unla-
beled competitor oligonucleotide containing the wild-
type C/EBP-binding site (TTATGCAAT; lane 7) inhibited
formation of the specific complex when it was added to
Effects of Ets-2 and activated Ras on the Tkdp-1 1000 bp pro- moter activity in NIH3T3 cells Figure 5
Effects of Ets-2 and activated Ras on the Tkdp-1 1000 
bp promoter activity in NIH3T3 cells. Luc activities are 
expressed relative to that of the basal activity of the 1000 bp 
construct. Data are shown as means ± SEM (n = 3). The fol-
lowing values differ significantly (p < 0.05): 1000 vs. Ets-
2+Ras and T-A72Ets-2+Ras; Ets-2+Ras vs. T-A72Ets-2+Ras.
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the reaction mixture. However, an unlabeled oligonucle-
otide possessing a mutated C/EBP-binding site (TTATc-
Cccc; lane 8) failed to compete in the binding reaction.
The addition of an antiserum directed against individual
C/EBPs only provided a major "supershift" when the anti-
C/EBP-β reagent was employed (lane 4). There was a
minor effect noted with anti-C/EBP-α (lane 3). Neither
anti-C/EBP-δ (lane 5) nor non-immune rabbit IgG (lane
6) had any effect. Thus C/EBP-β would appear to be the
major isoform of C/EBP that binds the TTATGCAAT ele-
ment present in the 140 bp minimal promoter of the
Tkdp-1 gene.
Interaction between C/EBP-β and Ets-2 in JEG-3 cells
Co-immunoprecipitation (Co-IP) and oligonucleotide
pull-down experiments were performed to demonstrate
the in vivo interaction between C/EBP-β and Ets-2 in JEG-
3 cells. For the former, endogenous Ets-2 in JEG-3 cell
extracts was allowed to form an immune complex with a
rabbit polyclonal Ets-2-specific immunoglobulin, col-
lected on Protein-A beads and then subjected to western
blot analysis with C/EBP-β-specific antiserum (Fig. 11A,
lane 3). The data indicate that endogenous C/EBP-β is
associated with Ets-2 in JEG-3 cell extracts. No C/EBP-β
protein was detected when non-immune rabbit IgG was
substituted for the anti-Ets-2 antiserum (lane 4). As posi-
tive control, endogenous C/EBP-β was collected with C/
EBP-β-specific antiserum and the western blot developed
with the same antiserum (lane 2).
When a streptavidin-bound, biotinylated ds oligonucle-
otide representing the C/EBP-binding region of the Tkdp-
1 promoter was used as a bait to collect proteins present
in JEG3 cells, the oligonucleotide was able to trap endog-
enous C/EBP-β (lane 3, Fig. 11B). This ability to bind C/
EBP-β was inhibited in the presence of an excess of unla-
beled wild type competitor oligonucleotide, but not by
unlabeled mutated competitor (lanes 5 versus 4). The C/
EBP-binding site containing biotinylated oligonucleotide
was able to trap Ets-2 as well as C/EBP-β (lane 3, Fig. 11C),
even though it did not possess a known Ets-binding
sequence. The Ets-2-specific bands were not detected
when excess unlabeled, wild-type competitor oligonucle-
otide was included in the reaction mixture (lane 4, Fig.
Effects of Ets-2 and activated PKA on the Tkdp-1 1000 bp promoter activity in JEG-3 cells Figure 6
Effects of Ets-2 and activated PKA on the Tkdp-1 1000 bp promoter activity in JEG-3 cells. Expression of the 1000 
bp promoter-Luc construct A) following co-transfection with activated PKA, activated PKA+PKI, mutPKA, Ets-2, Ets-2+acti-
vated PKA, Ets-2+activated PKA+PKI, Ets-2+mutPKA and B) in cells exposed to the PKA inhibitor H89 in presence and 
absence of co-transfected Ets-2. Luc activities are expressed relative to that of the basal activity of the 1000 bp construct and 
data are shown as mean ± SEM (n = 3). The following values are significantly different at P < 0.05: A) 1000 vs. 1000+PKA, 
1000+Ets-2, 1000+Ets-2+PKA; 1000+PKA vs. 1000+mutPKA, 1000+PKA+PKI; 1000+Ets-2+PKA vs. 1000+Ets-2+mutPKA, 
1000+Ets-2+PKA+PKI and B) 1000+PKA vs. 1000+PKA+3 μMH89, 1000+PKA+8 μMH89; 1000+PKA+12 μM H89; 1000+Ets-
2+PKA vs. 1000+Ets-2+PKA+3 μM H89, 1000+Ets-2+PKA+8 μM H89, 1000+Ets-2+PKA+12 μM H89
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11C). These data provide conclusive evidence that Ets-2
associates with C/EBP-β while the latter is bound to its
CCAAT-binding-sequence. The possibility that Ets-2
bound to the CCAAT/enhancer element directly is
unlikely in view of earlier data (Fig. 7).
Mutation of the AP-1-binding site does not affect the Ets-
2-responsiveness of the Tkdp-1 promoter
The 140 bp Tkdp-1 promoter possesses a conserved AP-1
element (-99 to -93) immediately downstream of the
CCAAT/enhancer element (-117 too -109). In order to
determine the functional importance of this site for tran-
scriptional activation of the promoter, site-directed muta-
genesis followed by transient transfection experiments
were performed. As demonstrated in Fig. 12A, mutation of
the AP-1 element caused up to 90% reduction in basal
activity and 74% reduction in PKA-dependent promoter
activation. This mutation did not affect the Ets-2-medi-
ated ovTkdp-1 promoter activation, although it reduced
the effect of the Ets-2 plus PKA combination on the pro-
moter by up to 65%. Together these data indicate that the
AP-1 element adjacent to the C/EBP-β-binding site is
important in regulating transcription from the Tkdp-1
minimal promoter and for activation of transcription by
the cAMP/PKA signaling pathway, but is not involved in
the recruitment of Ets-2 to the promoter.
The AP-1 element in the 140 bpTkdp-1 promoter interacts 
with C/EBP-β
Pull-down assays were conducted in JEG-3 extracts with a
biotinylated, ds oligonucleotide containing positions -99
to -93 of the Tkdp-1 promoter (Fig. 12B and 12C). Some
interactions between this element and several Jun family
transcription factors (c-Jun, Jun B, Jun D and p39) could
be demonstrated by western blotting (Fig. 12C). By con-
trast none of the Fos-related proteins (c-Fos, Fos B, Fra-1
and Fra-2) was pulled down from the JEG-3 cell extracts
(negative results not shown). Unexpectedly, this AP-1 ele-
ment-protein complex contained C/EBP-β, suggesting
that whatever bound to this sequence also associated with
C/EBP-β (Fig. 12B).
Expression of Ets-2 and C/EBP-β transcripts in conceptuses
RT-PCR analyses performed on RNA extracted from sheep
conceptuses/trophoblast at days 14, 15, 16, 17 and 25 of
pregnancy showed that C/EBP-β mRNA, like Ets-2 mRNA,
is expressed relatively uniformly over these days of con-
ceptus development (Fig. 1B and 1C). This expression pat-
Competition EMSA with recombinant Ets-2 protein and a 32P-labeled ds Ets-2 consensus oligonucleotide Figure 7
Competition EMSA with recombinant Ets-2 protein and a 32P-labeled ds Ets-2 consensus oligonucleotide. Lane 
1: labeled oligonucleotide+Ets-2-GST-fusion protein; lane 2: labeled oligonucleotide+GST protein; lane 3: labeled oligonucle-
otide+Ets-2-GST-fusion protein+anti-Ets-2 IgG; lane 4: labeled oligonucleotide+Ets-2-GST-fusion protein+unlabeled Ets-2 con-
sensus oligonucleotide (250-fold molar excess); lanes 5–10: labeled oligonucleotide+Ets-2-GST-fusion protein+unlabeled 
overlapping oligonucleotides from the Tkdp-1 promoter (-150 to +20) at 250-fold molar excess.
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tern is in sharp contrast to that of the Tkdp-1 gene, whose
expression pattern is maximal around day 17 and then
tails off by day 25.
Discussion
TKDP-1 is an abundant secretory product of the ruminant
placental trophoblast cells during the peri-implantation
stage of pregnancy, a period when the enlarging blastocyst
starts to signal its presence to the mother in preparation
for establishing an intimate contact with the uterine
endometrium [2,7,35]. This stage of conceptus develop-
ment is also marked by the production of IFN-τ, the pro-
tein responsible for "rescue" of the corpus luteum during
early pregnancy in ruminant ungulate species, such as cat-
tle, sheep, goat and deer. Like ovTKDP-1, IFN-τ is a prod-
uct of trophoblast mononuclear cells, and its production
rises sharply as the blastocyst expands and begins to elon-
gate, presumably in response to growth factors, hormones
and cytokines present in the uterine secretions of the
mother [2,11,12]. Many of such factors operate through
activation of established signal transduction pathways,
including the Ras/MAPK and cAMP/PKA pathways
[12,36,37]. Shutdown of expression after the trophoblast
begins to adhere to the uterine wall might be due to lack
of access of the adherent trophectoderm to these maternal
factors, which probably originate from the uterine glands
of the underlying endometrium. The striking similarity in
the expression patterns of ovTKDP-1 and IFN-τ, which is
illustrated in Fig. 1A, led us to speculate that the genes for
these two proteins might be controlled by similar tran-
scriptional mechanisms, involving the same transcription
factors and signal transduction pathways.
The starting point for our study on Tkdp-1 transcriptional
control was the Ets family transcription factor, Ets-2, a
homolog for the viral oncogene of the avian leukemia
virus E26 [38]. Although expressed widely in adult and
embryonic tissues, Ets-2 is required for placental develop-
ment in the mouse [39] and supports expression of several
genes, including the IFNT, whose expression provide a
phenotypic "signature" for trophectoderm [15-21,23].
The promoters of each of these genes possess functional
Ets-2-binding sites which, when mutated, cause almost
complete loss of reporter gene expression. Ets-2 tran-
scripts are certainly present in the ovine conceptus (Fig.
1B), and Ets-2 protein is expressed in trophectoderm of
bovine conceptuses of equivalent developmental stage
[22], but appears to be limiting for driving maximal
Effects of C/EBP-α, -β and -δ on the Tkdp-1 140 bp promoter activity in JEG-3 cells Figure 8
Effects of C/EBP-α, -β and -δ on the Tkdp-1 140 bp promoter activity in JEG-3 cells. Luc expression driven by the 
minimal promoter in cells co-transfected with each of the C/EBP isoforms A) in the absence and presence of over-expressed 
Ets-2 and B) in the presence of over-expressed Ets-2 and 250 μM 8-BrcAMP. Luc activities are expressed relative to that of the 
basal activity of the 140 bp promoter and data are shown as mean ± SEM (n = 3). The following values are significantly different 
at P < 0.05: A) 140 vs. Ets-2, C/EBP-α+Ets-2, C/EB-Pβ+Ets-2, C/EBP-δ+Ets-2 and B) 140 vs. cAMP+Ets-2, cAMP+Ets-2+C/EBP-
α, cAMP+Ets-2+C/EBP-β, cAMP+Ets-2+C/EBP-δ; cAMP+Ets-2 vs. cAMP+Ets-2+C/EBP-β, cAMP+Ets-2+C/EBP-δ. cAMP+Ets-
2+C/EBP-β is significantly different (P < 0.05) from both cAMP+Ets-2+C/EBP-α and cAMP+ Ets-2+C/EBP-δ.
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expression of reporter genes from IFNT and hCG subunit
gene promoters in human choriocarcinoma cells, such as
JAr and JEG3, and in 3T3 mouse fibroblasts [23]. Our first
goal, therefore, was to determine whether Ets-2 might
play a role, possibly a central one, in control of the Tkdp-
1 gene expression, just as it does in controlling the activi-
ties of other signature genes of trophectoderm.
Based on the fact that the Tkdp-1 promoter possessed sev-
eral sites that might bind Ets-2 or one of its relatives, tran-
sient transfection experiments were performed in JEG3
choriocarcinoma cells to test the effects of various Ets fam-
ily transcription factors on the Tkdp-1 promoter expres-
sion (Fig. 4A). As expected, Ets-2 proved most effective of
the factors tested and up-regulated the Tkdp-1 promoter
about as well as it did the IFNT promoter [12]. The ability
of Ets-2 to drive expression from the Tkdp-1 promoter in
3T3 cells required an activated MAPK pathway (Fig. 5)
and was at least partially dependent on the MAPK target
residue, Thr 72, in the so-called "pointed" domain of the
protein[23]. These results were entirely consistent with
Ets-2 effects on the IFNT and hCG subunit gene promoters
when they were examined in 3T3 cells [16,23,28]. In
human choriocarcinoma cells, expression was highly
responsive to over-expression of the catalytic subunit of
PKA. A combination of PKA and Ets-2 over-expression
could up-regulate the promoter over 700-fold (Fig. 6A).
Again, in all these respects, the Tkdp-1 promoter behaved
similarly to the IFNT, hCGα, and hCGβ  promoters
[11,16,17,23]. Finally, we have also demonstrated that
the Ets-2 effects on the Tkdp-1 promoter are silenced by
the expression of Oct-4 (Chakrabarty, A. and Roberts, R.
M., unpublished results), another feature shared with the,
hCGα, hCGβ, and IFNT genes [29,40,41]. These similari-
ties suggest that all these trophoblast-expressed genes
share a common transcriptional control mechanism, with
a central role played by Ets-2 in each, which allows the
genes to be up-regulated soon after the trophectoderm cell
lineage first emerges.
In the case of the IFNT, hCGα and hCGβ genes, however,
transactivation by Ets-2 is entirely dependent upon the
ability of the transcription factor to bind directly to DNA
at recognizable, although relatively diverse, Ets-2-binding
sequences [11,16,17,23,42]. Strikingly, the proximal/
minimal Tkdp-1 promoter region between 82 and 140 bp
from the tsp, which is responsive to Ets-2 (Fig. 2 and 4B),
seems physically incapable of forming a stable association
Effects of the CCAAT/enhancer element (-117 to -109) mutation on the Tkdp-1 140 bp promoter activity in A) JEG-3 and B)  NIH3T3 cells Figure 9
Effects of the CCAAT/enhancer element (-117 to -109) mutation on the Tkdp-1 140 bp promoter activity in A) 
JEG-3 and B) NIH3T3 cells. A) Basal, activated PKA, Ets-2, Ets-2+activated PKA-dependent activation of the wild type and 
C/EBP-mutated minimal promoter in JEG-3 cells. B) Basal, activated Ras, Ets-2, Ets-2+activated Ras-dependent activation of the 
wild type and C/EBP-mutated promoter in NIH3T3 cells. Luc activities are expressed relative to that of the basal activity of the 
140 bp promoter and data are shown as mean ± SEM (n = 3). Following values are significantly different at P < 0.05: A) 
140+PKA vs. C/EBPmut140+PKA; 140+Ets-2 vs. C/EBPmut140+Ets-2; 140+Ets-2+PKA vs. C/EBPmut140+Ets-2+PKA and B) 
140+Ets-2 vs. C/EBPmut140+Ets-2 and 140+Ets-2+Ras vs. C/EBPmut140+Ets-2+Ras.
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EMSA with 32P-labeled C/EBP oligonucleotide (-117 to -109) and JEG-3 cell extracts (CE) Figure 10
EMSA with 32P-labeled C/EBP oligonucleotide (-117 to -109) and JEG-3 cell extracts (CE). Lane 1: labeled oligonu-
cleotide+CE; lane 2: labeled oligonucleotide-CE; lane 3: labeled oligonucleotide+CE+C/EBP-α IgG; lane 4: labeled oligonucle-
otide+CE+C/EBP-β IgG; lane 5: labeled oligonucleotide+CE+C/EBP-δ IgG; lane 6: labeled oligonucleotide+CE+non-immune 
rabbit IgG; lanes 7–8: labeled oligonucleotide+CE+250-fold molar excess of unlabeled wild type (lane 7) and mutated (lane 8) 
C/EBP competitor oligonucleotides.
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C/EBP-β and Ets-2 interaction demonstrated by A) co-immunoprecipitation, B) and C) pull-down assays with biotinylated C/ EBP oligonucleotide (-117 to -109) in JEG-3 cell extracts (CE) Figure 11
C/EBP-β and Ets-2 interaction demonstrated by A) co-immunoprecipitation, B) and C) pull-down assays with 
biotinylated C/EBP oligonucleotide (-117 to -109) in JEG-3 cell extracts (CE). A) Lane 1: JEG-3 CE (positive control 
for western blot); lane 2: immunoprecipitation (IP) with C/EBP-β IgG (positive control for IP); lane 3: IP with Ets-2 IgG; lane 4: 
IP with non-immune rabbit IgG (negative control for IP). Western blot (WB) was performed with C/EBP-β IgG. B) WB per-
formed with C/EBP-β IgG as detection reagent following pull-down assays. Lane 1: JEG-3 CE (positive control for WB); lane 2: 
biotinylated C/EBP oligonucleotide; lane 3: JEG-3 CE+biotinylated C/EBP oligonucleotide; lane 4: JEG-3 CE+biotinylated C/EBP 
oligonucleotide+250-fold molar excess unlabeled mutated C/EBP oligonucleotide; lane 5: JEG-3 CE+biotinylated C/EBP oligo-
nucleotide+250-fold molar excess unlabeled wild type C/EBP oligonucleotide. C) WB with Ets-2 IgG as the detection agent fol-
lowing pull-down assays. Lane 1: JEG-3 CE (positive control for WB); lane 2: biotinylated C/EBP oligonucleotide; lane 3: JEG-3 
CE+biotinylated C/EBP oligonucleotide; lane 4: JEG-3 CE+biotinylated C/EBP oligonucleotide+250-fold molar excess unlabeled 
wild type C/EBP oligonucleotide.
12 3 4
WB:C/EBP-β IgG
1 2345
WB: C/EBP-β IgG
WB:Ets-2IgG
12 3 4
A B CBMC Molecular Biology 2007, 8:14 http://www.biomedcentral.com/1471-2199/8/14
Page 13 of 19
(page number not for citation purposes)
with Ets-2 in vitro (Fig. 7). The most obvious conclusion is
that Ets-2 must form an association with a second tran-
scription factor that binds within this critical region, and,
when so positioned, is able to influence transcription
from the Tkdp-1 gene promoter about as efficiently as it
does when it binds directly to the IFNT promoter.
The next goal, therefore, was to elucidate the mechanism
by which Ets-2 controls Tkdp-1 gene expression without a
direct interaction with the DNA. Our initial focus was on
a conserved CCAAT/enhancer element located between
117 and 109 bp up-stream of the tsp (Fig. 3). There are sev-
eral reasons to consider the possibility that a CCAAT-
binding protein might regulate the Tkdp-1 gene. First, C/
EBP-α, -β and -δ are expressed in human placental cells
[29]. Second, C/EBP-β transactivates multiple genes that
are expressed by trophoblast cells, including the gene for
the homeobox protein distal-less-3 (Dlx3) [43], a tran-
scription factor that binds to the IFNT promoter and co-
operatively enhances its Ets-2 responsiveness (Ezashi, T.
and Roberts, R. M.; unpublished data). Third, recent
experiments have suggested a crucial role for C/EBP-α and
-β in embryogenesis, since deletion of both genes results
in mortality around embryonic day 10–11 due to gross
Importance of the AP-1 element (-99 to -93) for the Tkdp-1.140 bp promoter activity in JEG-3 cells Figure 12
Importance of the AP-1 element (-99 to -93) for the Tkdp-1.140 bp promoter activity in JEG-3 cells. A) Effects of 
the AP-1 element mutation on the basal, activated PKA, Ets-2 and Ets-2+activated PKA-dependent activation of the 140 bp 
Tkdp-1 promoter-Luc reporter construct in JEG-3 cells. Luc activities are expressed relative to that of the basal activity of the 
140 bp promoter and data are shown as mean ± SEM (n = 3). Following values are significantly different at P < 0.05: 140+PKA 
vs. AP-1mut140+PKA and 140+Ets-2+PKA vs. AP-1mut140+Ets-2+PKA. B) and C) Pull-down assays with biotinylated AP-1 
oligonucleotide (-99 to -93 in the tkdp-1 promoter) and JEG-3 cell extracts(CE). Following pull-down a ssays, WB analysis was 
performed with B) C/EBP-β IgG and C) pan-Jun IgG. Lane 1: JEG-3 CE (positive control for WB); lane 2: biotinylated AP-1 oli-
gonucleotide; lane 3: JEG-3 CE+biotinylated AP-1 oligonucleotide. The molecular weight standards are shown on the left-hand 
side.
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failure in placental development [44]. Fourth, C/EBP-α
and -β have been demonstrated to interact with several Ets
family members, including Elk-1, Fli-1, Ets-1
[30,32,33,45]. Fifth, C/EBP proteins, particularly C/EBP-
β, are responsive to both cAMP/PKA and MAPK pathways
[34,46]. Activation of the cAMP/PKA pathway promotes
C/EBP-β gene transcription, nuclear translocation, recruit-
ment of transcriptional co-activators (e.g. CBP/p300) and
phosphorylation at specific serine residues [46-55], while
the major effect of the MAPK pathway on C/EBP-β is
mediated through phosphorylation at specific threonine
residues, which leads to its activation[55,56].
When over-expressed in JEG-3 cells, none of the C/EBP
isoforms -α, -β, and -δ had an effect on the 140 bp Tkdp-1
minimal promoter. In presence of Ets-2 (Fig. 8A), a mod-
est increase in promoter activity was observed. When Ets-
2+C/EBP-β-transfected cells were treated with 250 μM Br-
cAMP, a synergistic increase in promoter activity was
observed, particularly in presence of C/EBP-β (Fig. 8B).
Thus, in JEG-3 cells, maximal effects of the C/EBP proteins
on the Tkdp-1 promoter require the participation of both
Ets-2 and the cAMP/PKA signaling pathway. Transient
transfection experiments and EMSA indicated C/EBP-β
was the most potent of the C/EBP isoforms that bound to
the CCAAT/enhancer element (Fig. 8A and 8B).
Further importance of the CCAAT/enhancer element in
controlling transcriptional activity of the 140 bp Tkdp-1
promoter was demonstrated by mutational analysis (Fig.
9A and 9B). Not only was an intact CCAAT element
required for C/EBP-β binding and basal promoter activity,
but also for Ets-2- and Ets-2+PKA-mediated activation
(Fig. 9A). Thus, C/EBP-β bound to the CCAAT/enhancer
element is likely to be the target for the cAMP/PKA signal-
ing pathway and also responsible for recruiting Ets-2. Fur-
ther support for the importance of C/EBP-binding site in
Ets-2-dependent activation of the Tkdp-1 promoter came
from co-transfection experiments in NIH3T3 cells, where
the mutated promoter demonstrated markedly reduced
Ets-2 and Ets-2+Ras effects (Fig. 9B). Co-IP and pull-down
assays confirmed a direct association between C/EBP-β
and Ets-2 proteins in JEG-3 cells (Fig. 11A, B and 11C).
Together, these experiments indicate that C/EBP-β binds
to the Tkdp-1 promoter between -117 and -109 and that
Ets-2 is recruited to this site via protein-protein interaction
with C/EBP-β. It should be noted here that due to the una-
vailability of an appropriate ovine trophoblast cell line,
further demonstration of the in vivo association between
C/EBP-β and Ets-2 proteins in context of the ovTkdp-1 pro-
moter using the chromatin immunoprecipitation assay
was not possible.
Our next focus was on a putative AP-1 element at -99 to -
93, adjacent to the CCAAT/enhancer motif in the Tkdp-1
promoter (Fig. 3), since AP-1 family transcription factors,
especially c-Jun and c-Fos are known to interact with both
Ets and C/EBP proteins [49,57-61]. As shown by site-
directed mutagenesis and transfection experiments, this
AP-1 site appeared crucial for maintaining basal activity of
the Tkdp-1 promoter in JEG-3 cells, as well as for the full
PKA responsiveness of the promoter. On the other hand,
mutation of the AP-1 site had no effect on Ets-2 respon-
siveness (Fig. 12A). In other words, PKA-dependent acti-
vation of the Tkdp-1 promoter may be mediated by some
factor bound to the AP-1 site adjacent to the CCAAT/
enhancer motif. Pull down experiments with a broad
spectrum antibody that recognizes multiple members of
the Jun family demonstrated that some of these proteins
did indeed bind to this site (Fig. 12C). However, C/EBP-β
itself was also a part of the protein complex (Fig. 12B).
Since C/EBP proteins bind to DNA as either homo- or het-
erodimers [62], and C/EBP-β is known to form complexes
with c-Jun[63], it is tempting to speculate that the AP-1
site adjacent to the CCAAT element in the Tkdp-1 pro-
moter recruits a heterodimer consisting of C/EBP-β and a
member of the Jun family of proteins.
A search of the recent draft of the bovine genome
sequence (see website) [64] allowed us to identify the
putative bovine ortholog of the Tkdp-1  gene (between
positions 424335-407548 on contig no. NW_928686 on
chromosome 13). There is 89% sequence identity
between the ovine and bovine genes over the 140 bp
region directly upstream of the transcription start site
determined for the ovine gene (Additional data file 1 –
Fig. 3). The single base mutation in the CCAAT element in
the bovine gene (TTAcGCAAT versus TTATGCAAT) would
likely not destroy the core C/EBP-binding motif (TKNNG-
NAAK ; where K = T or G and N = any nucleotide) [65],
while the single base mutation in the AP-1-binding site
(TGACcCA versus TGACTCA) might well reduce its ability
to interact with typical AP-1 proteins. The high degree of
conservation in the C/EBP-β binding sequence main-
tained over the 17 million or so years since the lineage
leading to modern day cattle and sheep diverged provides
an additional argument for the importance of the CCAAT
motif.
Conclusion
The pattern of expression of the ovine trophoblast Kunitz
domain protein-1 produced by the trophectoderm during
the peri-implantation stage of embryo development is
almost identical to that of IFN-tau and directed by the
same transcription factor, Ets-2, in combination with the
protein kinase A and mitogen-activated protein kinase sig-
nal transduction pathways, but does not involve direct
binding of Ets-2 to promoter control elements. Instead,
up-regulation of the gene is accomplished indirectly
through protein-protein interactions with C/EBP-β. MostBMC Molecular Biology 2007, 8:14 http://www.biomedcentral.com/1471-2199/8/14
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importantly, the work reported here demonstrates how
Ets-2, a key transcription factor for trophoblast differenti-
ation and function, can control expression of genes hav-
ing similar spatial and temporal expression patterns via
very different mechanisms.
Methods
Reverse transcription polymerase chain reaction (RT-PCR) 
analyses of sheep conceptus RNA
Animal husbandry and surgical procedures were per-
formed according to the protocols approved by the Ani-
mal Care and Use Committee at the University of
Missouri-Columbia [66, 3097]. Expression patterns of
TKDP-1, IFN-τ, Ets-2, C/EBP-β, and ribosomal protein
S25 mRNAs were determined by RT-PCR on sheep con-
ceptus/ trophoblast RNA collected on days 14, 15, 16, 17,
19 and 25 of pregnancy. RNA was extracted by using RNA
STAT-60 reagent (Tel-Test, Friendswood, TX)[66]. RT reac-
tions were performed on 1–2 μg RNA (pre-treated with
deoxyribonuclease; Ambion, Inc., Austin, TX) by using
Super-Script III ribonuclease H- reverse transcriptase (Inv-
itrogen, Carlsbad, CA) in presence of 50 μM oligodeox-
ythymidine (dT) primer. RT reaction product (5 μl) was
used for each 50 μl PCR reaction with 100 ng of sense and
anti-sense primers (Additional data file 1 – Table 1) and
PicoMaxx High Fidelity PCR Master Mix (Stratagene, La
Jolla, CA). Twenty-five PCR cycles were used to amplify
TKDP-1, IFN-τ and S25 messages, while 30–35 cycles were
needed to visualize the Ets-2 and C/EBP-β-mRNAs. PCR
products were resolved through 1.5% TAE (Tris-acetate-
EDTA)-agarose gels at 100 volts for 1 h and stained with
ethidium bromide. In order to confirm that RNA prepara-
tions were free of DNA, control RT reactions were per-
formed without initial reverse transcription. As positive
controls we employed 10 ng plasmid DNAs encoding the
open reading frames for ovTKDP-1, ovIFN-τ4, Ets-2, C/
EBP-β and ribosomal protein S25.
Constructs, antibodies and cell culture reagents
The transcription start point (tsp) of the Tkdp-1 gene [Gen-
bank:AY940665] is located at ~35 bp downstream of a
putative TATA-like sequence (1730 in the Tkdp-1 gene)
within the 1 Kbp region upstream of the 5/ untranslated
region (UTR) [2]. Chimeric promoter-reporter plasmids
were constructed by amplifying the 1 Kbp region
upstream of the 5/ UTR by PCR to generate 1000 bp, 558
bp, 352 bp, 254 bp, 192 bp, 140 bp and 82 bp fragments.
After verifying their sequences, these products were
inserted between the HindIII and XhoI restriction sites on
the pGL2 Basic promoter-less plasmid containing the Luc
reporter gene (Promega, Madison, WI). Additional data
file 1 – Table 2 lists all sense primers used in combination
with a common anti-sense primer for generating the PCR
fragments. Expression plasmids for chicken Ets-1, human
Ets-2, mouse Elf-1, human Fli-1, mouse PEA-3, mouse
PU.1 were provided by Dr. Michael Ostrowski, Ohio State
University, Columbus, OH. The expression vectors for
mouse GABP-α and -β1 were from Dr. M. E. Martin, Uni-
versity of Missouri, Columbia, MO. The GABP-α and -β1
plasmids were used together, as GABP functions as a het-
erodimer. The mutated Ets-2 construct (pCGNEts-2A72)
and constitutively active Rasexpression vector pHO6T1 or
its parental vector Homer6 have been described elsewhere
[2]. The plasmid used to express the constitutively active
form of the catalytic subunit of PKA expression construct
was a generous gift from Dr. Mark S. Roberson, Cornell
University College of Veterinary Medicine, Ithaca, NY. The
plasmids for the catalytically inactive PKA expression con-
struct (mutPKA), in which the ATP-binding codon, lysine
72, had been mutated to methionine; [23], and the PKA
inhibitor, PKI, [67] were provided by Dr. Richard A. Mau-
rer, University of Iowa, Iowa City, Iowa. Constructs for rat
C/EBP-α, mouse C/EBP-β and mouse C/EBP-δ were
obtained from Dr. Steven L. McKnight (Southwestern
Medical School, Dallas, TX). The β-galactosidase  gene
driven by the Rouse sarcoma virus LTR (pRSVLTR-β-gal)
was provided by Dr. R. V. Guntaka, University of Missouri,
Columbia, MO. The Renilla-Luciferase reporter plasmid
driven by Simian virus 40 enhancer and promoter (pRL-
SV40) was purchased from Promega (Madison, WI).
The CCAAT/enhancer element between -117 and -109
and the AP-1 element between -99 and -93 of the Tkdp-1
promoter were mutated by using the Quik Change Site-
directed Mutagenesis kit from Stratagene (La Jolla, CA).
Sequences of the sense and anti-sense primers are listed in
additional data file 1 – Table 3. The fidelity of mutation
was checked by sequencing with the pGL2 Basic vector-
specific GL-1 and GL-2 primers (Promega, Madison, WI).
Affinity purified rabbit polyclonal antibodies for C/EBP-α
(sc-61), -β (sc-150), -δ (sc-151), Ets-2 (sc-351), pan-Jun (sc-
44; recognizes c-Jun, Jun B, Jun D, p39), pan-Fos (sc-413;
recognizes c-Fos, Fos B, Fra-1, Fra-2) and non-immune
rabbit IgG (sc-2027) were purchased from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA).
Fetal bovine serum was purchased from Harlan (Indiana-
polis, IN). Media for mammalian cell culture (MEM and
DMEM), cell culture-grade sodium pyruvate, L-glutamine
and penicillin-streptomycin solutions were purchased
from Invitrogen (Carlsbad, CA). Peptidase and phos-
phatase inhibitors, 8-bromo-cAMP (8-Br-cAMP), and
MEM non-essential amino acid solution were purchased
from Sigma (Saint Louis, MO).
Cell culture, transfection and statistical analyses
Transfection experiments were performed in either the
human choriocarcinoma JEG-3 cells or the mouse fibrob-
last NIH3T3 cells (for experiments with activated Ras).BMC Molecular Biology 2007, 8:14 http://www.biomedcentral.com/1471-2199/8/14
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Both cell lines were purchased from ATCC (Manassas, VA)
and maintained in 5% CO2 in air and at 37°C in media
(MEM for JEG-3 and DMEM for 3T3 cells) containing
10% heat-inactivated fetal bovine serum and 50 U/ml
penicillin and 50 μg/ml streptomycin. Medium for JEG-3
cells was supplemented with 1 mM sodium pyruvate and
1× non-essential amino acid. DMEM for 3T3 cells was
supplemented with 4 mM L-glutamine. The day before
transfection, cells were plated in 60 mm (JEG-3 cells) or
35 mm dishes (3T3 cells) at a density of 2.5 × 105 cells/60
mm dish (JEG-3 cells) or 1.7 × 105 cells/35 mm dish (3T3
cells).
Transient transfection experiments (repeated at least twice
in triplicate) in JEG-3 and NIH3T3 cells were performed
with calcium phosphate [68] and FuGene 6 reagents
(Roche Molecular Biochemicals, Indianapolis, IN),
respectively. The pRSVLTR-β-gal (0.025 μg/60 mm dish)
and pRL-SV40 (0.008 μg/35 mm dish) constructs were
used as internal normalization controls in JEG-3 and 3T3
cells, respectively. Each set of transfections in 60 mm dish
was performed with 3.5 μg of Luc reporter construct and
0.5 μg of the plasmid DNA for each transcription factor.
Cells in each 35 mm dish were transfected with 1.7 μg of
Luc construct, 0.25 μg Ets-2 or PKA expression construct
and 0.6 μg activated Ras expression construct. Total
amount of DNA was kept constant in all transfections by
including appropriate empty vector. In some experiments,
cells were treated with 250 μM 8-Br-cAMP approximately
10 h after transfection. Luc and β-galactosidase enzyme
assays were usually performed on cell lysates 44–48 h
after transfection with commercially available kits (Luc
and Dual Luc Assays system from Promega, Madison, WI
and Galactolight Plus systems from Applied Biosystems,
Foster City, CA) as 15 sec light outputs from a Turner
Designs model 20e luminometer (Sunnyvale, CA).
Transfection results were expressed as average fold induc-
tion in Luc reporter activity ± SEM. Statistical test on dif-
ferences in relative Luc activities (normalized values) were
performed by one way ANOVA followed by Tukey's mul-
tiple comparison tests (GraphPad Prism version 4).
Electrophoretic mobility shift assay (EMSA)
EMSA was carried out with 32P-labeled ds Ets-2 oligonu-
cleotides (35 fmole) [69] (Additional data file 1 – Table 4)
and 2 μg of ovEts-2-GST fusion protein [21] (with GST as
control). Competition was provided by addition of either
a 250-fold molar excess of unlabeled Ets-2 consensus oli-
gonucleotide or each of six overlapping oligonucleotides
spanning the -150 bp to + 20 bp region on the Tkdp-1 pro-
moter (Table 4 in additional data file 1 – data; tsp = +1).
Competitor oligonucleotides were added prior to the
addition of the labeled oligonucleotide to the binding
reaction mixtures. Procedures for DNA binding reactions
and electrophoresis have been described previously [23].
The specificity of Ets-2 binding was verified by the ability
of 0.3 μg of Ets-2 antibody to retard the DNA-protein
complex during electrophoresis.
EMSA was also performed with the labeled, ds CCAAT/
enhancer element consensus sequence (35 fmol) from the
Tkdp-1 gene (between -117 and -109) and 10 μg of JEG-3
cell extracts prepared with 200 mM (pH 7.8) sodium
phosphate buffer, 0.5% triton X-100, 0.5 mM dithiothre-
itol and 1× peptidase inhibitor cocktail (Sigma, St. Louis,
MO). The specificity of DNA-protein complex formation
was verified by adding 250-fold molar excess of unlabeled
wild type or mutated C/EBP oligonucleotide (Additional
data file 1 – Table 4). In order to identify which of the
three C/EBP isoforms among -α, -β and -δ bound to the
CCAAT/enhancer element from the Tkdp-1 gene, 0.4 μg of
affinity purified rabbit polyclonal antibody specific to
each these transcription factors was added to each reac-
tion.
Co-immunoprecipitation reactions (Co-IP)
Rabbit IgG TrueBlot kit (eBioscience, Inc., San Diego, CA)
was used forCo-IP experiments with JEG-3 cells treated
with 250 μM 8-Br-cAMP for 24 h prior to cell lysis. Cell
extracts were prepared with 200 mM (pH 7.8) sodium
phosphate buffer, 0.5% triton X-100, 0.5 mM dithiothre-
itol and 1× each of the peptidase and phosphatase inhib-
itor cocktails. For immunoprecipitation (IP), 3 μg of each
of the rabbit Ets-2 antibody, rabbit C/EBP-β antibody and
non-immune rabbit IgG were used per mg of protein in
cell extracts. Immunoprecipitated samples were resolved
through 10% SDS-PAGE under denaturing conditions
and protein bands were transferred onto PVDF mem-
branes (Immobilon-P by Millipore Billerica, MA). West-
ern blotting was performed with a 1:500 dilution of rabbit
polyclonal C/EBP-β antibody in blocking solution (25
mM Tris-HCl, pH 7.3, 150 mM NaCl, 0.1% tween-20 and
5% non-fat dry milk). Following incubation with primary
antibody, the blot was treated with horseradish peroxi-
dase (HRP) conjugated anti-rabbit IgG (eBioscience, San
Diego, CA) at 1:1000 dilution in blocking solution. Mem-
branes were developed with the Phototype-HRP Western
Blot Detection System from Cell Signaling Technology,
Inc., Beverly, MA, and recorded on Kodak BioMax Light
Film (Kodak, Rochester, NY) according to the manufac-
turers' instructions.
Pull-down assays
Pull-down assays from JEG-3 cell extracts were performed
with biotinylated ds oligonucleotides representing C/EBP
and AP-1-binding elements (Additional data file 1 – Table
5). Each pair of sense and anti-sense oligonucleotides was
prepared and modified (3/  biotinylation of the sense
strand) by MWG-Biotech (High Point, NC). BiotinylatedBMC Molecular Biology 2007, 8:14 http://www.biomedcentral.com/1471-2199/8/14
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ds oligonucleotide were incubated with 50 μl of immobi-
lized streptavidin (Pierce Biotechnology, Rockford, IL) at
4°C for 1–2 h, followed by addition of 0.5 to 1.0 mg of
JEG-3 cell extracts (prepared with 25 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5 mM dithioth-
reitol and 1× each of the peptidase and phosphatase
inhibitor cocktails (Sigma, Saint Louis, MO) at 4°C for
overnight with gentle mixing. The immobilized DNA-pro-
tein complex was washed (3×) with cold 25 mM Tris-HCl,
pH 7.5, 150 mM NaCl and boiled with 5× SDS-loading
dye under denaturing condition and resolved through
10% SDS-PAGE gels. Proteins were transferred from the
gel to the PVDF membrane as described above. Western
blotting was performed with 1:750 dilution of each of the
rabbit polyclonal Ets-2, C/EBP-β, pan-Jun and pan-Fos
antibodies and developed by the Western-Star Systems
from Applied Biosystems (Bedford, MA) according to the
manufacturer's instruction.
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